THOUSAND OAKS, Calif. , May 16, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday , May 21, 2025. Kave Niksefat , senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors... Read More

THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Wednesday, May 14, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast... Read More

THOUSAND OAKS, Calif. , May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway , chairman and chief executive officer. Key results... Read More

THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

Total Investment in the State to Exceed $1.4 Billion , 750 U.S. Jobs THOUSAND OAKS, Calif. , April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility, bringing the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion . "Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's... Read More

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif. , April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA ® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after... Read More

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif. , April 3, 2025 /PRNewswire/ -- Amgen... Read More

Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing * Late-Breaking Data to be Presented at AAN 2025 THOUSAND OAKS, Calif. , March 13, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA ® (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG). The results... Read More

Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif. , and TOKYO , March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis... Read More

THOUSAND OAKS, Calif. , March 4, 2025 /PRNewswire/ - - Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025 , to all stockholders of record as of the close of business on May 16, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in... Read More

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif. , March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for surgery... Read More

THOUSAND OAKS, Calif. , Feb. 28, 2025 /PRNewswire/ - - Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday , March 5, 2025. Jay Bradner , executive vice president of Research and Development at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news... Read More

THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday , Feb. 19, 2025. Jean-Charles Soria , senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media,... Read More

THOUSAND OAKS, Calif. , Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35 th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday , Feb. 12, 2025. Narimon Honarpour, senior vice president of global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media,... Read More

THOUSAND OAKS, Calif. , Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four... Read More

THOUSAND OAKS, Calif. , Jan. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and... Read More

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer... Read More

THOUSAND OAKS, Calif. , Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The... Read More

IMDYLLTRA® is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy, including platinum-based chemotherapy 1 Lung cancer is the third most common cancer in the UK, with more than 49,000 cases diagnosed in the UK between 2017 and 2019 2 Small cell lung cancer (SCLC) accounts for approximately 15% of all lung... Read More

THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in... Read More

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia... Read More

Investment Establishes Second Facility in Holly Springs ; Builds on Previous $550M Commitment THOUSAND OAKS, Calif. , Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina . This brings the company's total planned investment in Holly Springs to more than $1.5 billion , building on its previously announced $550... Read More

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related... Read More

THOUSAND OAKS, Calif. , Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024 . Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and... Read More

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau... Read More

THOUSAND OAKS, Calif. , Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024 , to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other... Read More

Howard Chang , M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif. , Nov. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Howard Chang , M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay... Read More

MITIGATE Phase 3 Study Results Reinforce Promise of UPLIZNA ® as the First Potential Treatment tor IgG4-RD Phase 4 AGILE Data Support Shortening KRYSTEXXA ® Infusion Time THOUSAND OAKS, Calif. , Nov. 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in... Read More

THOUSAND OAKS, Calif. , Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of... Read More

THOUSAND OAKS, Calif. , Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday , Nov. 13, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the... Read More

Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo THOUSAND OAKS, Calif. , Nov. 7, 2024 /PRNewswire/ - - Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE ® (tezepelumab-ekko) had a... Read More

THOUSAND OAKS, Calif. , Oct. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2024. "Strong growth in sales and earnings this quarter reflects the momentum we're building throughout our business. We continue to invest heavily in our rapidly advancing pipeline, with a focus on delivering innovative therapies across our core therapeutic areas," said Robert A. Bradway ,... Read More

THOUSAND OAKS, Calif. , Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The dividend will be paid on December 9, 2024 , to all stockholders of record as of the close of business on November 18, 2024 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of... Read More

THOUSAND OAKS, Calif. , Oct. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2024 financial results on Wednesday, October 30, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

MINT Study Results Show Clinically Meaningful and Statistically Significant Efficacy in AChR+ and MuSK+ Patients First and Only Phase 3 Placebo-Controlled gMG Trial for a Biologic That Tapered Corticosteroid Use THOUSAND OAKS, Calif. , Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ®... Read More

Campaign Encourages Open Dialogue With Doctor About Unmanaged Symptoms to Find the Right Treatment Option THOUSAND OAKS, Calif. , Oct. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) has partnered with multi-talented actress, producer and entrepreneur La La Anthony to share her personal journey living with plaque psoriasis, and to inspire people to be open with their doctors about how the disease affects their daily lives. As... Read More

THOUSAND OAKS, Calif. , Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA ® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) Thyroid Eye Disease (TED) by Japan's Ministry of Health, Labour and Welfare (MHLW). TED is a serious, progressive and potentially vision-threatening rare autoimmune disease that can cause proptosis... Read More

THOUSAND OAKS, Calif. , Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m. PT on Tuesday, Sept. 24, 2024 , to discuss new topline clinical data from the rocatinlimab (AMG 451/KHK4083) and UPLIZNA ® (inebilizumab-cdon) Phase 3 programs. Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and other members... Read More

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif. , Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and... Read More

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif. , Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRA TM (tarlatamab-dlle), a first-in-class delta-like ligand... Read More

THOUSAND OAKS, Calif. , Aug. 30, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday , Sept. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be... Read More

THOUSAND OAKS, Calif. , Aug. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference at 9:15 a.m. ET on Wednesday , Sept. 4, 2024. Robert A. Bradway , chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the... Read More

First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. , Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis in children and adolescents ages... Read More

THOUSAND OAKS, Calif. , Aug. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter 2024. "With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth," said Robert A. Bradway , chairman and chief executive officer. Key results include: For the second... Read More

THOUSAND OAKS, Calif. , Aug. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will be paid on September 6, 2024 , to all stockholders of record as of the close of business on August 16, 2024 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients... Read More

THOUSAND OAKS, Calif. , Aug. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2024 financial results on Tuesday, August 6, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy Alone First and Only Bispecific T-cell Engager (BiTE ® ) Therapy for Consolidation Treatment Regardless of Measurable Residual Disease (MRD) Status THOUSAND OAKS, Calif. , June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has... Read More

Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA ® and Progress in Addressing Sjögren's Disease THOUSAND OAKS, Calif. , June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna . The 27 abstracts from Amgen-sponsored and... Read More

THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45 th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday , June 10, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast... Read More

Data Show a Statistically Significant 87% Reduction in IgG4-RD Flares, With Primary and All Key Secondary Endpoints Met First Randomized, Placebo-Controlled Trial to Demonstrate Benefit in IgG4-RD THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial ( NCT04540497 ) evaluating... Read More

THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday , June 6, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Ian Thompson , senior vice president, U.S. Business Operations at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and... Read More

Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral Presentation THOUSAND OAKS, Calif. , May 28, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology... Read More

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire ® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD)... Read More

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif. , May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug... Read More

THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday , May 20, 2024 following the presentation of new data from TEZSPIRE ® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional... Read More

THOUSAND OAKS, Calif. , May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday , May 14, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast... Read More

THOUSAND OAKS, Calif. , May 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through our pipeline, we are excited about delivering attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the first quarter,... Read More

Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS ® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement THOUSAND OAKS, Calif. , May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS)... Read More

THOUSAND OAKS, Calif. , April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

THOUSAND OAKS, Calif. , April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious,... Read More

Planning Underway for Phase 3 Development of Tezepelumab in COPD THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International... Read More

SPROUT 52-Week Data Demonstrate Durable Response and Consistent Safety Profile of Oral Otezla in Children with Moderate to Severe Plaque Psoriasis Late-Breaking Phase 3 Study of Otezla in Palmoplantar Pustulosis Achieves Primary and Secondary Endpoints at 16 Weeks THOUSAND OAKS, Calif. , March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of... Read More

THOUSAND OAKS, Calif. , March 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will be paid on June 7, 2024 , to all stockholders of record as of the close of business on May 17, 2024 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by... Read More

THOUSAND OAKS, Calif. , Feb. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 44 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday , March 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, and Paul Burton , senior vice president and chief medical officer at Amgen, will present at the conference. The webcast will be broadcast over the internet... Read More

THOUSAND OAKS, Calif. , Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio , the newest in its global operations network and the most advanced facility to date. "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway , chairman... Read More

THOUSAND OAKS, Calif. , Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon , executive vice president of Global Commercial Operations at Amgen, Jay Bradner ,... Read More

THOUSAND OAKS, Calif. , Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34 th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday , Feb. 14, 2024. Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon , executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney , senior vice... Read More

THOUSAND OAKS, Calif. , Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. "2023 was another year of performance and progress for our company," said Robert A. Bradway , chairman and chief executive officer. "Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen... Read More

THOUSAND OAKS, Calif. , Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and... Read More

REYKJAVIK, Iceland , Jan. 29, 2024 /CNW/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland , Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects... Read More

THOUSAND OAKS, Calif. , Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The... Read More

FDA Has Issued New Postmarketing Requirement LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval THOUSAND OAKS, Calif. , Dec. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS ® (sotorasib).... Read More

James Bradner , M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer David M. Reese, M.D., Named Executive Vice President and Chief Technology Officer THOUSAND OAKS, Calif. , Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology, underscoring the advancement of the... Read More

Sponsorship of the Golf Event Continues Following Horizon Acquisition Golfers Shane Lowry , Pádraig Harrington, Séamus Power and Brendan Lawlor Will Become Amgen Golf Ambassadors THOUSAND OAKS, Calif. , Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023 . Horizon... Read More

Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC 1 If Approved, Tarlatamab Would be the First BiTE ® Therapy for a Major Solid Tumor FDA Target Action Date is June 12, 2024 THOUSAND OAKS, Calif. , Dec. 13, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend and comes as the Company continues to invest in innovation and deleverage its balance sheet. The dividend will be paid on March 7, 2024 , to all stockholders of record as... Read More

Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO ® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS ® (carfilzomib) as an Important Treatment Option for Relapsed or Refractory Multiple Myeloma Additional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS ® ) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif.... Read More

THOUSAND OAKS, Calif. , Nov. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday , Nov. 29, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen, and Paul Burton , senior vice president and chief medical officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously... Read More

New Repatha ® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a) Amgen Provides Updates on Efforts to Advance Bold Ambition of Halving the Number of Heart Attacks and Strokes by 2030 THOUSAND OAKS, Calif. , Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new... Read More

FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla ® (apremilast) in patients with early oligoarticular psoriatic arthritis. FOREMOST is the first placebo-controlled study designed to specifically assess people with... Read More

First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those With Systemic Disease Results From Crossover Period Provide Further Evidence of the Clinical Efficacy and Safety of Dazodalibep in Sjögren's THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational... Read More

THOUSAND OAKS, Calif. , Nov. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA ® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD). The data will be presented at the American Society of Nephrology Kidney Week, taking place... Read More

Breadth of Research Reflects Amgen's Commitment to Rheumatology Data Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis THOUSAND OAKS, Calif. , Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon... Read More

THOUSAND OAKS, Calif. , Oct. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2023 1 . "We are excited about our pipeline progress and our operating performance in the third quarter," said Robert A. Bradway , chairman and chief executive officer. "With the completion of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad... Read More

THOUSAND OAKS, Calif. , Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023 , before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5:00 a.m. PT . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

THOUSAND OAKS, Calif. , Oct. 24, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023. The dividend will be paid on December 8, 2023 , to all stockholders of record as of the close of business on November 17, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious... Read More

First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C - Mutated Metastatic Colorectal Cancer Results Featured in a Presidential Symposium at ESMO and Simultaneously Published in the New England Journal of Medicine (NEJM) THOUSAND OAKS, Calif. , Oct. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS ® (sotorasib) (960... Read More

Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine (NEJM) Tarlatamab is an Investigational Delta-Like Ligand 3 (DLL3) Targeting BiTE ® Molecule THOUSAND OAKS, Calif. , Oct. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from... Read More

THOUSAND OAKS, Calif. , Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday , Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from tarlatamab,... Read More

Results From Phase 2 DeLLphi-301 Trial Highlight Potential of Tarlatamab, First BiTE in Patients With Previously Treated SCLC Pivotal Phase 3 CodeBreaK 300 Study Data Support LUMAKRAS ® (sotorasib) Plus Vectibix ® (panitumumab) Combination in KRAS G12C-Mutated mCRC Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen's T-Cell Engagers in mCRPC THOUSAND OAKS, Calif. , Oct. 16, 2023... Read More

Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines THOUSAND OAKS, Calif. , Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion . "Today marks an exciting milestone as we welcome Horizon employees to Amgen and... Read More

REYKJAVIK, Iceland , Oct. 4, 2023 /CNW/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using... Read More

Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients Inaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs THOUSAND OAKS, Calif. , Sept. 20, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Amgen Partners of Choice, a new network that brings together... Read More

THOUSAND OAKS, Calif. , Sept. 11, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday , Sept. 14, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news... Read More

In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65% THOUSAND OAKS, Calif. , Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer... Read More

THOUSAND OAKS, Calif. , Sept. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. ET on Tuesday, Sept. 12, 2023 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general... Read More

THOUSAND OAKS, Calif. and DUBLIN , Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon... Read More

THOUSAND OAKS, Calif. , Aug. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Wednesday , Sept. 6, 2023. Amgen will also present at the Citi Global Healthcare Conference at 1:00 p.m. ET on Thursday , Sept. 7, 2023. Peter H. Griffith , executive vice president and chief financial officer at Amgen, and Murdo Gordon , executive vice president of global... Read More

Amgen is Changing the Cardiovascular Disease Treatment Landscape With New Research on Innovative Lipid Management New Olpasiran Phase 2 Data Demonstrates Continued Reduction of Lp(a) Nearly a Year After the Last Dose Amgen Convenes First LDL Awareness to Action Implementation Consortium THOUSAND OAKS, Calif. , Aug. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2... Read More

THOUSAND OAKS, Calif. , Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS ® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting... Read More

Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer Positive Top-Line Results for LUMAKRAS ® (Sotorasib) Plus Vectibix ® (Panitumumab) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif. , Aug. 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2023. "We had a very strong quarter, serving more patients across all geographies and therapeutic categories and... Read More

THOUSAND OAKS, Calif. , Aug. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will be paid on September 8, 2023 , to all stockholders of record as of the close of business on August 18, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses... Read More

THOUSAND OAKS, Calif. , July 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer,... Read More

Conversion From Accelerated to Full Approval Reinforces BLINCYTO as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission THOUSAND OAKS, Calif. , June 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO ® (blinatumomab) for the treatment of adults and... Read More

THOUSAND OAKS, Calif. , June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44 th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday , June 14, 2023. Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the... Read More

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows Improved PFS vs Docetaxel Across Key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study LUMAKRAS Plus Vectibix ® (panitumumab) and FOLFIRI Combination Show ORR of 55% in Previously Treated KRAS G12C-Mutated Metastatic CRC... Read More

New LUMAKRAS ® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS G12C-Mutated Advanced NSCLC Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE ® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases Novel Combinations Show Encouraging Safety and... Read More

MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients Exploratory Analysis Examines Effects of Otezla on Cardiometabolic Parameters THOUSAND OAKS, Calif. , May 30, 2023 /PRNewswire/ - - Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory... Read More

THOUSAND OAKS, Calif. , May 26, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday , May 31, 2023. David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors... Read More

THOUSAND OAKS, Calif. , May 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc: "Amgen is disappointed by the FTC's decision and remains committed to completing this acquisition, which will bring significant benefits to patients suffering from very... Read More

Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment Longer Duration of Treatment With Prolia Was Associated With Greater Improvements in Fracture Risk Reduction Data is From Real-World Study with Nearly Half a Million Patients Comparing Prolia to Alendronate THOUSAND OAKS, Calif. , May 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today... Read More

THOUSAND OAKS, Calif. , May 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday , May 9, 2023. David M. Reese , M.D., executive vice president of Research and Development and Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over... Read More

THOUSAND OAKS, Calif. , April 27, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. "We delivered 14% volume growth driven by the breadth of our portfolio and strong demand for our products globally," said Robert A. Bradway , chairman and chief executive officer. "We look forward to closing the acquisition of Horizon Therapeutics and joining forces to reach more... Read More

THOUSAND OAKS, Calif. , April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief executive... Read More

Appeals Court Affirms Validity of Patent Expiring in 2028 THOUSAND OAKS, Calif. , April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals ( USA ), Inc. ("Zydus"). Today's decision affirms... Read More

THOUSAND OAKS, Calif. , March 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023 . Susan Sweeney , senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and... Read More

THOUSAND OAKS, Calif. , March 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023. The dividend will be paid on June 8, 2023 , to all stockholders of record as of the close of business on May 18, 2023 . About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by... Read More

THOUSAND OAKS, Calif. , March 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday , March 8, 2023. Murdo Gordon , executive vice president of Global Commercial Operations and Peter H. Griffith , executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet... Read More

Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level Amgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S. THOUSAND OAKS, Calif. , March 1, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today... Read More

Unique Community-Based Partnership With the Association of Black Cardiologists and Morehouse School of Medicine to Identify Study Sites and Participants Observational Study to Better Understand Associations Between Lp(a) Levels and Atherosclerotic Cardiovascular Disease (ASCVD) in an Underrepresented Patient Population THOUSAND OAKS, Calif. , Feb. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the African... Read More

THOUSAND OAKS, Calif. , Feb. 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023 . Susan Sweeney , senior vice president, Global Marketing, Access and Capabilities at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media,... Read More

Now Offers Patients the Choice of Administration at Home or in a Doctor's Office THOUSAND OAKS, Calif. , Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE ® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. 1 First approved by the FDA in December... Read More

THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen ( NASDAQ : AMGN ) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier today. The transcript, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com ,... Read More

AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. "We executed effectively in 2022, delivering strong volume growth, advancing numerous first-in-class medicines in our... Read More

Four Years of Real-World Experience in More Than 300,000 Patients and Over 60 Countries 1 THOUSAND OAKS, Calif. , Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®* (adalimumab), is now available in the United States . AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016. 2,3 "With today's... Read More

THOUSAND OAKS, Calif. , Jan. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET . Participating in the call from Amgen will be Robert A. Bradway , chairman and chief... Read More

Biotherapeutics Company to Receive lab Space, Mentoring and Other Benefits THOUSAND OAKS, Calif. , Jan. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California . Nammi Therapeutics will receive one year of lab space at BioLabs LA at The Lundquist Institute (TLI) as well as additional... Read More

THOUSAND OAKS, Calif. , Jan. 4, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 J.P. Morgan Healthcare Conference at 6:45 p.m. ET on Monday, January 9, 2023 . Robert A. Bradway , chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The... Read More

At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group THOUSAND OAKS, Calif. , Dec. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial. This is the first study to... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023. The dividend will be paid on March 8, 2023 , to all stockholders of record as of the close of business on February 15, 2023 . This represents a 10% increase from that paid in each of the previous four quarters. About Amgen Amgen is committed... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community following the announced acquisition of Horizon Therapeutics at 8:00 a.m. ET on Monday, December 12, 2022 . Robert A. Bradway , chairman and chief executive officer, along with members of the executive team, will participate. The webcast will be broadcast over the internet simultaneously and will be... Read More

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Summary The board of directors of Horizon Therapeutics plc (the " Company " or " Horizon ") and the board of directors of Amgen Inc. (" Amgen ") are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (" Acquirer Sub "), a newly formed private limited company wholly owned by Amgen, which is unanimously... Read More

AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks Initiating Phase 2 Study in Early 2023 THOUSAND OAKS, Calif. , Dec. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide... Read More

THOUSAND OAKS, Calif. , Nov. 28, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday , Dec. 5, 2022. David M. Reese , M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1... Read More

THOUSAND OAKS, Calif. , Nov. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022 . David M. Reese , M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the... Read More